BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Itoh H, Ochiai T. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003;133:24-31. [PMID: 12563234 DOI: 10.1067/msy.2003.31] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Ma X, Zhao K, Guo W, Yang S, Zhu X, Xiang J, Zhang Y, Li H. Salvage Lymphadenectomy Versus Salvage Radiotherapy/Chemoradiotherapy for Recurrence in Cervical Lymph Node After Curative Resection of Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2015;22:624-9. [DOI: 10.1245/s10434-014-4008-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
2 Jingu K, Nemoto K, Matsushita H, Takahashi C, Ogawa Y, Sugawara T, Nakata E, Takai Y, Yamada S. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer. 2006;6:50. [PMID: 16515704 DOI: 10.1186/1471-2407-6-50] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
3 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Li SH. The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis. Cancers (Basel) 2019;11:E451. [PMID: 30934987 DOI: 10.3390/cancers11040451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Kagaya A, Shimada H, Shiratori T, Kuboshima M, Nakashima-Fujita K, Yasuraoka M, Nishimori T, Kurei S, Hachiya T, Murakami A, Tamura Y, Nomura F, Ochiai T, Matsubara H, Takiguchi M, Hiwasa T. Identification of a novel SEREX antigen family, ECSA, in esophageal squamous cell carcinoma. Proteome Sci. 2011;9:31. [PMID: 21696638 DOI: 10.1186/1477-5956-9-31] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
5 Jingu K, Kaneta T, Nemoto K, Takeda K, Ogawa Y, Ariga H, Koto M, Sakayauchi T, Takai Y, Takahashi S, Yamada S. 18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol 2010;15:184-90. [DOI: 10.1007/s10147-010-0044-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sobhani N, D'Angelo A, Wang X, Young KH, Generali D, Li Y. Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci 2020;21:E4087. [PMID: 32521648 DOI: 10.3390/ijms21114087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Port JL, Nasar A, Lee PC, Paul S, Stiles BM, Andrews W, Altorki NK. Definitive Therapy for Isolated Esophageal Metastases Prolongs Survival. The Annals of Thoracic Surgery 2012;94:413-20. [DOI: 10.1016/j.athoracsur.2012.03.075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kimoto T, Yamazaki H, Suzuki G, Aibe N, Masui K, Tatekawa K, Sasaki N, Fujiwara H, Shiozaki A, Konishi H, Nakamura S, Yamada K. Local field radiotherapy without elective nodal irradiation for postoperative loco-regional recurrence of esophageal cancer. Jpn J Clin Oncol 2017;47:809-14. [PMID: 28903531 DOI: 10.1093/jjco/hyx092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kosuga T, Shiozaki A, Fujiwara H, Ichikawa D, Okamoto K, Komatsu S, Otsuji E. Treatment outcome and prognosis of patients with lymph node recurrence of thoracic esophageal squamous cell carcinoma after curative resection. World J Surg 2011;35:798-804. [PMID: 21312037 DOI: 10.1007/s00268-011-0978-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
10 Makuuchi Y, Honda K, Osaka Y, Kato K, Kojima T, Daiko H, Igaki H, Ito Y, Hoshino S, Tachibana S. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 2013;104:1045-1051. [PMID: 23648090 DOI: 10.1111/cas.12187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
11 van Genderen ME, Lima A, de Geus H, Klijn E, Wijnhoven B, Gommers D, van Bommel J. Serum C-Reactive Protein as a Predictor of Morbidity and Mortality in Intensive Care Unit Patients After Esophagectomy. The Annals of Thoracic Surgery 2011;91:1775-9. [DOI: 10.1016/j.athoracsur.2011.02.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
12 Shimada H. p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2018;2:266-73. [PMID: 30003189 DOI: 10.1002/ags3.12179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
13 Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, Shuto K, Shimizu T, Akutsu Y, Tanizawa Y, Hayashi H, Ochiai T. Location and clinical impact of solitary lymph node metastasis in patients with thoracic esophageal carcinoma. The American Journal of Surgery 2006;192:306-10. [DOI: 10.1016/j.amjsurg.2006.01.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 Gao F, Li C, Gu Y, Huang J, Wu P. CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients. Eur J Radiol 2013;82:e70-5. [PMID: 23040418 DOI: 10.1016/j.ejrad.2012.09.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
15 Kim SJ, Hyun SH, Moon SH, Cho YS, Yi HK, Shim YM, Choi JY, Kim BT, Lee KH. Total FDG lesion number on PET/CT predicts survival of esophageal carcinoma patients with recurrence following curative surgery. Q J Nucl Med Mol Imaging 2020;64:211-8. [PMID: 29697218 DOI: 10.23736/S1824-4785.18.03041-8] [Reference Citation Analysis]
16 Yamashita H, Kitayama J, Taguri M, Nagawa H. Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response. World J Surg. 2009;33:1298-1305. [PMID: 19347392 DOI: 10.1007/s00268-009-9992-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
17 Li H, Li Q, Lian J, Chu Y, Fang K, Xu A, Chen T, Xu M. MLL2 promotes cancer cell lymph node metastasis by interacting with RelA and facilitating STC1 transcription. Cell Signal 2020;65:109457. [PMID: 31676369 DOI: 10.1016/j.cellsig.2019.109457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Akhtar J, Wang Z, Yu C, Zhang ZP, Bi MM. STMN-1 Gene: A Predictor of Survival in Stage IIA Esophageal Squamous Cell Carcinoma After Ivor-Lewis Esophagectomy? Ann Surg Oncol 2014;21:315-21. [DOI: 10.1245/s10434-013-3215-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
19 Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, Nabeya Y, Shuto K, Hayashi H, Tanizawa T. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 2006;97:554-561. [PMID: 16734736 DOI: 10.1111/j.1349-7006.2006.00206.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
20 Shimada H, Shiratori T, Okazumi S, Matsubara H, Nabeya Y, Shuto K, Akutsu Y, Hayashi H, Isono K, Ochiai T. Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg 2008;206:48-56. [PMID: 18155568 DOI: 10.1016/j.jamcollsurg.2007.06.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
21 Lin DC, Du XL, Wang MR. Protein alterations in ESCC and clinical implications: a review. Dis Esophagus. 2009;22:9-20. [PMID: 18564170 DOI: 10.1111/j.1442-2050.2008.00845.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 4.5] [Reference Citation Analysis]
22 Maruyama K, Motoyama S, Anbai A, Usami S, Sato Y, Shibuya K, Yoshino K, Nakatsu T, Minamiya Y, Ogawa JI. Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy. Dis Esophagus 2011;24:166-71. [PMID: 20946135 DOI: 10.1111/j.1442-2050.2010.01119.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
23 Kunisaki C, Makino H, Takagawa R, Yamamoto N, Nagano Y, Fujii S, Kosaka T, Ono HA, Otsuka Y, Akiyama H, Ichikawa Y, Shimada H. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg 2008;12:802-10. [PMID: 17952515 DOI: 10.1007/s11605-007-0385-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
24 Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, Mitsuhashi N. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol 2008;15:2451-7. [PMID: 18592318 DOI: 10.1245/s10434-008-0016-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
25 Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 2006;14:999-1011. [PMID: 16708213 DOI: 10.1007/s00520-006-0079-9] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 5.8] [Reference Citation Analysis]
26 Vats HS, Banerjee TK, Resnick J, Khan Q. Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy. Clin Med Res 2006;4:184-8. [PMID: 16988098 DOI: 10.3121/cmr.4.3.184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Sudo T, Iwaya T, Nishida N, Sawada G, Takahashi Y, Ishibashi M, Shibata K, Fujita H, Shirouzu K, Mori M. Expression of mesenchymal markers vimentin and fibronectin: the clinical significance in esophageal squamous cell carcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S324-S335. [PMID: 22644514 DOI: 10.1245/s10434-012-2418-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
28 Sawada G, Niida A, Hirata H, Komatsu H, Uchi R, Shimamura T, Takahashi Y, Kurashige J, Matsumura T, Ueo H, Takano Y, Ueda M, Sakimura S, Shinden Y, Eguchi H, Sudo T, Sugimachi K, Yamasaki M, Tanaka F, Tachimori Y, Kajiyama Y, Natsugoe S, Fujita H, Tanaka Y, Calin G, Miyano S, Doki Y, Mori M, Mimori K. An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma. PLoS One 2015;10:e0139808. [PMID: 26465158 DOI: 10.1371/journal.pone.0139808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Shimada H, Yajima S, Oshima Y, Hiwasa T, Tagawa M, Matsushita K, Nomura F. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus 2012;9:131-40. [DOI: 10.1007/s10388-012-0332-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sainger RNS, Shah MH, Desai AA, Shukla SN, Shah PM, Telang SD, Patel PS. Clinical Significance of Serum p53 Antibodies in Oral Cancer. Tumori 2006;92:134-9. [DOI: 10.1177/030089160609200209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
31 Shimada H, Okazumi S, Matsubara H, Shiratori T, Akutsu Y, Nabeya Y, Tanizawa T, Matsushita K, Hayashi H, Isono K, Ochiai T. Long-term Results after Dissection of Positive Thoracic Lymph Nodes in Patients with Esophageal Squamous Cell Carcinoma. World J Surg 2008;32:255-61. [DOI: 10.1007/s00268-007-9213-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
32 Schipper PH, Cassivi SD, Deschamps C, Rice DC, Nichols FC, Allen MS, Pairolero PC. Locally Recurrent Esophageal Carcinoma: When is Re-Resection Indicated? The Annals of Thoracic Surgery 2005;80:1001-6. [DOI: 10.1016/j.athoracsur.2005.03.099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
33 Makino T, Yamasaki M, Miyata H, Tanaka K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Solitary Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma: Surgical Failure or Systemic Disease? Ann Surg Oncol 2016;23:2087-93. [DOI: 10.1245/s10434-015-5086-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
34 Wang Y, Wang Y, Wang S, Tong Y, Jin L, Zong H, Zheng R, Yang J, Zhang Z, Ouyang E, Zhou M, Zhang X. GIDB: a knowledge database for the automated curation and multidimensional analysis of molecular signatures in gastrointestinal cancer. Database (Oxford) 2019;2019:baz051. [PMID: 31089686 DOI: 10.1093/database/baz051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Okada R, Shimada H, Otsuka Y, Tsuchiya M, Ishii J, Katagiri T, Maeda T, Kubota Y, Nemoto T, Kaneko H. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma. Surg Today 2017;47:1492-9. [PMID: 28508195 DOI: 10.1007/s00595-017-1540-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Akhtar J, Wang Z, Jiang WP, Bi MM, Zhang ZP. Stathmin overexpression identifies high risk for lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma patients. J Gastroenterol Hepatol 2014;29:944-50. [PMID: 24372619 DOI: 10.1111/jgh.12498] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
37 Liu Q, Xia Y, Chen Y, Zhang J, Deng J, Zhao K. A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence. Radiat Oncol 2020;15:75. [PMID: 32268925 DOI: 10.1186/s13014-020-01518-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, Li SH. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy. Sci Rep 2017;7:41785. [PMID: 28134308 DOI: 10.1038/srep41785] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
39 Shimada H, Matsubara H, Okazumi S, Isono K, Ochiai T. Improved Surgical Results in Thoracic Esophageal Squamous Cell Carcinoma: A 40-year Analysis of 792 Patients. J Gastrointest Surg 2008;12:518-26. [DOI: 10.1007/s11605-007-0280-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
40 Shimada H, Shiratori T, Yasuraoka M, Kagaya A, Kuboshima M, Nomura F, Takiguchi M, Ochiai T, Matsubara H, Hiwasa T. Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma. BMC Cancer. 2009;9:232. [PMID: 19604354 DOI: 10.1186/1471-2407-9-232] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
41 Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Ann Surg 2009;249:392-6. [PMID: 19247024 DOI: 10.1097/SLA.0b013e3181949e9f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
42 Shimada H, Nagata M, Cho A, Takiguchi N, Kainuma O, Soda H, Ikeda A, Nabeya Y, Yajima S, Yamamoto H. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957-1961. [PMID: 24241479 DOI: 10.1007/s00595-013-0787-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
43 Shang L, Wang M. Molecular alterations and clinical relevance in esophageal squamous cell carcinoma. Front Med. 2013;7:401-410. [PMID: 24002746 DOI: 10.1007/s11684-013-0286-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
44 Zong M, Feng W, Wan L, Yu X, Yu W. LncRNA TUG1 promotes esophageal cancer development through regulating PLK1 expression by sponging miR-1294. Biotechnol Lett 2020;42:2537-49. [PMID: 33009634 DOI: 10.1007/s10529-020-02984-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, Ochiai T. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006;97:380-386. [PMID: 16630135 DOI: 10.1111/j.1349-7006.2006.00192.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
46 Jingu K, Ariga H, Nemoto K, Narazaki K, Umezawa R, Takeda K, Koto M, Sugawara T, Kubozono M, Miyata G. Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83:172-177. [PMID: 22079727 DOI: 10.1016/j.ijrobp.2011.06.1978] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
47 Huang W, Li B, Gong H, Yu J, Sun H, Zhou T, Zhang Z, Liu X. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: A report of 1077 cases. Radiother Oncol. 2010;95:229-233. [PMID: 20189259 DOI: 10.1016/j.radonc.2010.01.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
48 Shimada H, Okazumi S, Matsubara H, Shiratori T, Shuto K, Akutsu Y, Nabeya Y, Hayashi H, Ochiai T. Surgical outcome after the clearance of abdominal metastatic lymph nodes in 138 patients with thoracic esophageal carcinoma. The American Journal of Surgery 2007;193:448-52. [DOI: 10.1016/j.amjsurg.2006.06.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
49 Takahashi K, Miyashita M, Nomura T, Makino H, Futami R, Kashiwabara M, Katsuta M, Tajiri T. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus. 2007;20:117-122. [PMID: 17439594 DOI: 10.1111/j.1442-2050.2007.00656.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
50 Hiyoshi Y, Morita M, Kawano H, Otsu H, Ando K, Ito S, Miyamoto Y, Sakamoto Y, Saeki H, Oki E, Ikeda T, Baba H, Maehara Y. Clinical significance of surgical resection for the recurrence of esophageal cancer after radical esophagectomy. Ann Surg Oncol. 2015;22:240-246. [PMID: 25124469 DOI: 10.1245/s10434-014-3970-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
51 Shimizu H, Shiozaki A, Fujiwara H, Komatsu S, Ichikawa D, Okamoto K, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Kokuba Y, Otsuji E. Predictive factors for early recurrence in patients with esophageal squamous cell carcinoma after curative esophagectomy. Esophagus 2012;9:17-24. [DOI: 10.1007/s10388-011-0308-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Mori M, Doki Y. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenterol Surg. 2019;3:169-180. [PMID: 30923786 DOI: 10.1002/ags3.12222] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
53 Fujishiro T, Shuto K, Hayano K, Satoh A, Kono T, Ohira G, Tohma T, Gunji H, Narushima K, Tochigi T. Preoperative hepatic CT perfusion as an early predictor for the recurrence of esophageal squamous cell carcinoma: initial clinical results. Oncol Rep. 2014;31:1083-1088. [PMID: 24452736 DOI: 10.3892/or.2014.2992] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 Wakahara T, Ueno N, Maeda T, Kanemitsu K, Yoshikawa T, Tsuchida S, Toyokawa A. Is the Glasgow Prognostic Score Applicable to Both Early- and Advanced-Stage Gastric Cancers? Gastroenterology Res 2017;10:359-65. [PMID: 29317944 DOI: 10.14740/gr943w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One 2015;10:e0143080. [PMID: 26717416 DOI: 10.1371/journal.pone.0143080] [Cited by in Crossref: 113] [Cited by in F6Publishing: 116] [Article Influence: 16.1] [Reference Citation Analysis]
56 Ueda M, Iguchi T, Masuda T, Nakahara Y, Hirata H, Uchi R, Niida A, Momose K, Sakimura S, Chiba K, Eguchi H, Ito S, Sugimachi K, Yamasaki M, Suzuki Y, Miyano S, Doki Y, Mori M, Mimori K. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. Oncotarget. 2016;7:62280-62291. [PMID: 27556701 DOI: 10.18632/oncotarget.11409] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 9.8] [Reference Citation Analysis]
57 Zhang N, Gu M, Wang J, Wu S. Comparison of nodal irradiation dose using radiotherapy for patients with thoracic esophageal cancer. Oncol Lett 2020;19:1042-50. [PMID: 31897217 DOI: 10.3892/ol.2019.11178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Iguchi T, Ueda M, Masuda T, Nambara S, Kidogami S, Komatsu H, Sato K, Tobo T, Ogawa Y, Hu Q, Saito T, Hirata H, Sakimura S, Uchi R, Hayashi N, Ito S, Eguchi H, Sugimachi K, Maehara Y, Mimori K. Identification of UHRF2 as a Negative Regulator of Epithelial-Mesenchymal Transition and Its Clinical Significance in Esophageal Squamous Cell Carcinoma. Oncology 2018;95:179-87. [PMID: 29909415 DOI: 10.1159/000488860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
59 Motoyama S, Saito R, Okuyama M, Maruyama K, Nanjo H, Ogawa J. Long-term survival after salvage resection of recurrent esophageal cancer with anterior mediastinal lymph node involvement: report of a case. Surg Today 2006;36:827-30. [PMID: 16937289 DOI: 10.1007/s00595-006-3242-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Hiraki T, Yasui K, Mimura H, Gobara H, Mukai T, Hase S, Fujiwara H, Tajiri N, Naomoto Y, Yamatsuji T, Shirakawa Y, Asami S, Nakatsuka H, Hanazaki M, Morita K, Tanaka N, Kanazawa S. Radiofrequency Ablation of Metastatic Mediastinal Lymph Nodes during Cooling and Temperature Monitoring of the Tracheal Mucosa to Prevent Thermal Tracheal Damage: Initial Experience. Radiology 2005;237:1068-74. [DOI: 10.1148/radiol.2373050234] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
61 Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, Matsubara H, Nomura F, Ochiai T. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 2009;33:272-7. [PMID: 19052812 DOI: 10.1007/s00268-008-9821-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
62 Chao YK, Chan SC, Chang HK, Liu YH, Wu YC, Hsieh MJ, Tseng CK, Liu HP. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. Eur J Surg Oncol 2009;35:289-94. [PMID: 18396384 DOI: 10.1016/j.ejso.2008.02.014] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
63 Li J, Wen Y, Xiang Z, Du H, Geng L, Yang X, Zhang Y, Bai J, Dai T, Feng G, Liu L, Du X. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. Radiother Oncol 2021;154:201-6. [PMID: 32980382 DOI: 10.1016/j.radonc.2020.09.042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R, Yaremko B, Younus J, Sanatani M, Vincent M, Dingle B, Fortin D, Inculet R. What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer? Curr Oncol 2010;17:46-51. [PMID: 21151409 DOI: 10.3747/co.v17i6.561] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
65 Sawada G, Niida A, Uchi R, Hirata H, Shimamura T, Suzuki Y, Shiraishi Y, Chiba K, Imoto S, Takahashi Y, Iwaya T, Sudo T, Hayashi T, Takai H, Kawasaki Y, Matsukawa T, Eguchi H, Sugimachi K, Tanaka F, Suzuki H, Yamamoto K, Ishii H, Shimizu M, Yamazaki H, Yamazaki M, Tachimori Y, Kajiyama Y, Natsugoe S, Fujita H, Mafune K, Tanaka Y, Kelsell DP, Scott CA, Tsuji S, Yachida S, Shibata T, Sugano S, Doki Y, Akiyama T, Aburatani H, Ogawa S, Miyano S, Mori M, Mimori K. Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. Gastroenterology. 2016;150:1171-1182. [PMID: 26873401 DOI: 10.1053/j.gastro.2016.01.035] [Cited by in Crossref: 143] [Cited by in F6Publishing: 149] [Article Influence: 23.8] [Reference Citation Analysis]
66 Shimada H, Shiratori T, Okazumi S, Matsubara H, Shuto K, Akutsu Y, Narushima K, Nabeya Y, Hayashi H, Ochiai T. Surgical Outcome of Elderly Patients 75 Years of Age and Older with Thoracic Esophageal Carcinoma. World J Surg 2007;31:773-9. [DOI: 10.1007/s00268-007-0606-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
67 Jingu K, Umezawa R, Yamamoto T, Matsushita H, Ishikawa Y, Kozumi M, Kubozono M, Takahashi N, Kadoya N, Takeda K. Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer. Jpn J Clin Oncol 2017;47:200-5. [PMID: 28031356 DOI: 10.1093/jjco/hyw195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
68 Su XD, Zhang DK, Zhang X, Lin P, Long H, Rong TH. Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma. J Thorac Dis. 2014;6:949-957. [PMID: 25093092 DOI: 10.3978/j.issn.2072-1439.2014.07.14] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
69 Motoyama S, Kitamura M, Saito R, Maruyama K, Okuyama M, Ogawa J. Outcome and Treatment Strategy for Mid- and Lower-Thoracic Esophageal Cancer Recurring Locally in the Lymph Nodes of the Neck. World J Surg 2006;30:191-8. [DOI: 10.1007/s00268-005-0092-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
70 Nakatani M, Migita K, Matsumoto S, Wakatsuki K, Ito M, Nakade H, Kunishige T, Kitano M, Sho M. Prognostic Significance of the Prognostic Nutritional Index in Patients with Recurrent Esophageal Squamous Cell Carcinoma. Nutrition and Cancer 2018;70:467-73. [DOI: 10.1080/01635581.2018.1445771] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
71 Hirashima K, Watanabe M, Shigaki H, Imamura Y, Ida S, Iwatsuki M, Ishimoto T, Iwagami S, Baba Y, Baba H. Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. J Gastroenterol. 2014;49:1040-1046. [PMID: 23821018 DOI: 10.1007/s00535-013-0855-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
72 Bharat A, Crabtree T. Management of advanced-stage operable esophageal cancer. Surg Clin North Am 2012;92:1179-97. [PMID: 23026277 DOI: 10.1016/j.suc.2012.07.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
73 Chen Y, Lu Y, Wang Y, Yang H, Xia Y, Chen M, Song H, Li T, Li D, Wang J, Li S, Wang J. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus 2014;27:134-40. [PMID: 23088212 DOI: 10.1111/j.1442-2050.2012.01440.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
74 Zhou ZG, Zhen CJ, Bai WW, Zhang P, Qiao XY, Liang JL, Gao XS, Wang SS. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy. Radiat Oncol 2015;10:54. [PMID: 25888966 DOI: 10.1186/s13014-015-0358-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
75 Matkovic E, Schwalbe M, Matkowskyj KA. Pathologic Features of Esophageal and Gastric Malignancies. Cancer Treat Res 2016;168:17-43. [PMID: 29206017 DOI: 10.1007/978-3-319-34244-3_2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
76 Shimada H, Nabeya Y, Matsubara H, Okazumi S, Shiratori T, Shimizu T, Aoki T, Shuto K, Akutsu Y, Ochiai T. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg. 2006;191:250-254. [PMID: 16442955 DOI: 10.1016/j.amjsurg.2005.07.035] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 6.0] [Reference Citation Analysis]
77 Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol. 2012;188:136-142. [PMID: 22218502 DOI: 10.1007/s00066-011-0023-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
78 Kulshrestha R, Gupta A, Sharma DN, Singh K. Brachytherapy for Oesophageal Carcinoma: A Comprehensive Review of Literature and Techniques. J Radiother Pract. [DOI: 10.1017/s1460396920001120] [Reference Citation Analysis]
79 Peng XE, Chen HF, Hu ZJ, Shi XS. Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China. BMC Med Genet 2015;16:15. [PMID: 25927305 DOI: 10.1186/s12881-015-0156-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
80 Hwang CC, Nieh S, Lai CH, Tsai CS, Chang LC, Hua CC, Chi WY, Chien HP, Wang CW, Chan SC, Hsieh TY, Chen JR. A retrospective review of the prognostic value of ALDH-1, Bmi-1 and Nanog stem cell markers in esophageal squamous cell carcinoma. PLoS One 2014;9:e105676. [PMID: 25148045 DOI: 10.1371/journal.pone.0105676] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
81 Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, Shimizu T, Shuto K, Hayashi H, Ochiai T. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg 2006;30:1441-9. [PMID: 16871357 DOI: 10.1007/s00268-005-0462-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 4.7] [Reference Citation Analysis]
82 Sasagawa H, Shiozaki A, Iitaka D, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Nakashima S, Kinoshita O, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Kokuba Y, Otsuji E. Ki-67 labeling index as an independent prognostic factor in human esophageal squamous cell carcinoma. Esophagus 2012;9:195-202. [DOI: 10.1007/s10388-012-0336-6] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
83 Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Uenosono Y, Ishigami S, Owaki T, Aikou T. The role of salvage surgery for recurrence of esophageal squamous cell cancer. Eur J Surg Oncol. 2006;32:544-547. [PMID: 16567077 DOI: 10.1016/j.ejso.2006.02.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
84 Suzuki T, Yajima S, Ishioka N, Nanami T, Oshima Y, Washizawa N, Funahashi K, Otsuka S, Nemoto T, Shimada H. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma. Esophagus 2018;15:294-300. [PMID: 29959634 DOI: 10.1007/s10388-018-0629-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
85 Hsu PK, Wang BY, Huang CS, Wu YC, Hsu WH. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg. 2011;15:558-565. [PMID: 21327531 DOI: 10.1007/s11605-011-1458-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.3] [Reference Citation Analysis]